Fund shareholders of BioCryst Pharmaceuticals Inc
ISIN US09058V1035 · United States · LEI 549300Z0INP1Z5NP6J59
- Fund shareholders
- 234
- Of which ETFs
- 52 182 other funds
- Value held
- ≈ 617.4M $ 616.9M $ · 398.3K €
- Share of capital
- 25.8 % of 255.5M shares on Jul 31, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| ULTRA SMALL CAP PROFUND ProFunds | 2,552 | 23.4K $ | 0.04 % | 0.00 % | as of Apr 30, 2026 ↗ |
| The Gabelli ABC Fund Gabelli Investor Funds Inc | 2,360 | 22.5K $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
| 1290 VT GAMCO Mergers & Acquisitions Portfolio EQ Advisors Trust | 2,360 | 22.5K $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Enterprise Mergers and Acquisitions Fund Gabelli 787 Fund, Inc. | 2,360 | 22.5K $ | 0.04 % | 0.00 % | as of Mar 31, 2026 ↗ |
| WisdomTree U.S. SmallCap Quality Growth Fund WisdomTree Trust | 2,350 | 22.4K $ | 0.23 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Guggenheim Multi-Hedge Strategies Fund Rydex Series Funds | 2,093 | 19.9K $ | 0.21 % | 0.00 % | as of Mar 31, 2026 ↗ |
| PD Small-Cap Value Index Portfolio PACIFIC SELECT FUND | 1,831 | 17.4K $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Small Company Value Portfolio Wilshire Mutual Funds Inc | 1,830 | 17.4K $ | 0.08 % | 0.00 % | as of Mar 31, 2026 ↗ |
| SA Franklin Tactical Opportunities Portfolio SUNAMERICA SERIES TRUST | 1,779 | 16.3K $ | 0.01 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Abacus FCF Small Cap Leaders ETF Abacus FCF ETF Trust | 1,682 | 15.4K $ | 1.26 % | 0.00 % | as of Apr 30, 2026 ↗ |
| State Street Balanced Index Fund STATE STREET INSTITUTIONAL INVESTMENT TRUST | 1,460 | 13.9K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| American Century Small Cap Growth Insights ETF American Century ETF Trust | 1,413 | 12.4K $ | 0.14 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Knights of Columbus U.S. ALL CAP INDEX FUND ADVISORS' INNER CIRCLE III | 1,316 | 12.1K $ | 0.00 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Wilshire 5000 Index Fund Wilshire Mutual Funds Inc | 1,207 | 11.5K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Avantis U.S. Equity ETF American Century ETF Trust | 1,145 | 10K $ | 0.00 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Russell 2000 2x Strategy Fund Rydex Dynamic Funds | 1,109 | 10.6K $ | 0.02 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Small-Cap Equity Portfolio PACIFIC SELECT FUND | 1,096 | 10.4K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Innovator U.S. Small Cap Managed 10 Buffer ETF Innovator ETFs Trust | 1,062 | 9.7K $ | 0.13 % | 0.00 % | as of Apr 30, 2026 ↗ |
| New Covenant Growth Fund NEW COVENANT FUNDS | 1,030 | 9.8K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| SmallCap Value Fund II Principal Funds, Inc | 818 | 7.5K $ | 0.00 % | 0.00 % | as of Apr 30, 2026 ↗ |
| PROFUND VP ULTRA SMALL CAP ProFunds | 757 | 7.2K $ | 0.05 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Avantis U.S. Quality ETF American Century ETF Trust | 623 | 5.5K $ | 0.00 % | 0.00 % | as of Feb 28, 2026 ↗ |
| PROFUND VP SMALL CAP ProFunds | 572 | 5.4K $ | 0.05 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Fidelity Flex Small Cap Focused Index Fund Fidelity Salem Street Trust | 564 | 5.2K $ | 0.03 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Russell 2000 Fund Rydex Series Funds | 510 | 4.9K $ | 0.04 % | 0.00 % | as of Mar 31, 2026 ↗ |
| SMALL-CAP PROFUND ProFunds | 413 | 3.8K $ | 0.05 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Russell 2000 1.5x Strategy Fund Rydex Series Funds | 305 | 2.9K $ | 0.05 % | 0.00 % | as of Mar 31, 2026 ↗ |
| E*TRADE No Fee Total Market Index Fund E Trade Trust | 248 | 2.3K $ | 0.00 % | 0.00 % | as of Apr 30, 2026 ↗ |
| ProShares Hedge Replication ETF ProShares Trust | 240 | 2.1K $ | 0.01 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Columbia Research Enhanced Small Cap ETF Columbia ETF Trust I | 219 | 2.1K $ | 0.07 % | 0.00 % | as of Mar 31, 2026 ↗ |
| ProShares Russell 2000 Dynamic Buffer ETF ProShares Trust | 72 | 630 $ | 0.06 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Russell 2000(R) 1.5x Strategy Fund Rydex Variable Trust | 59 | 561.7 $ | 0.02 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Simplify Piper Sandler US Small-Cap PLUS Income ETF Simplify Exchange Traded Funds | 1 | 9.5 $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| VIFAG 2002, SICAV S.A. GESALCALA, S.A., S.G.I.I.C. | 398.3K € | 0.48 % | as of Dec 31, 2025 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| Invesco Biotechnology & Genome ETF Invesco Exchange-Traded Fund Trust | 3.42 % | as of Apr 30, 2026 ↗ |
| ALGER HEALTH SCIENCES FUND ALGER FUNDS | 1.98 % | as of Apr 30, 2026 ↗ |
| Virtus Biotech Etf ETFis Series Trust I | 1.93 % | as of Apr 30, 2026 ↗ |
| AMG GW&K Small Cap Growth Fund AMG Funds IV | 1.53 % | as of Apr 30, 2026 ↗ |
| Abacus FCF Small Cap Leaders ETF Abacus FCF ETF Trust | 1.26 % | as of Apr 30, 2026 ↗ |
| AMG GW&K Small Cap Core Fund AMG Funds | 0.99 % | as of Mar 31, 2026 ↗ |
| VOYA SMALL COMPANY PORTFOLIO Voya VARIABLE PORTFOLIOS INC | 0.99 % | as of Mar 31, 2026 ↗ |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 0.85 % | as of Mar 31, 2026 ↗ |
| Voya MI Dynamic Small Cap Fund Voya Equity Trust | 0.85 % | as of Feb 28, 2026 ↗ |
| PROFUND VP BIOTECHNOLOGY ProFunds | 0.83 % | as of Mar 31, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 233 | +19 | 66,031,606 | +11.2 % |
| 2026Q1 | 214 | -9 | 59,373,114 | +2.7 % |
| 2025Q4 | 223 | +2 | 57,804,615 | +2.8 % |
| 2025Q3 | 221 | +24 | 56,213,881 | +0.5 % |
| 2025Q2 | 197 | +11 | 55,916,727 | +0.4 % |
| 2025Q1 | 186 | -2 | 55,692,608 | -4.1 % |
| 2024Q4 | 188 | +9 | 58,074,742 | +9.1 % |
| 2024Q3 | 179 | +6 | 53,244,751 | -10.8 % |
| 2024Q2 | 173 | +7 | 59,680,824 | +10.8 % |
| 2024Q1 | 166 | -13 | 53,858,374 | +7.8 % |
| 2023Q4 | 179 | 49,976,776 |
Institutional managers
290 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| BlackRock, Inc. | 22,650,988 | 215.6M $ | as of Mar 31, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 15,827,186 | 150.7M $ | as of Mar 31, 2026 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 15,038,000 | 143.2M $ | as of Mar 31, 2026 |
| STATE STREET CORP | 12,208,360 | 116.2M $ | as of Mar 31, 2026 |
| TCG Crossover Management, LLC | 11,020,968 | 104.9M $ | as of Mar 31, 2026 |
| JANUS HENDERSON GROUP PLC | 8,908,506 | 84.9M $ | as of Mar 31, 2026 |
| PERCEPTIVE ADVISORS LLC | 7,434,033 | 70.8M $ | as of Mar 31, 2026 |
| Vestal Point Capital, LP | 7,025,000 | 66.9M $ | as of Mar 31, 2026 |
| TWO SIGMA INVESTMENTS, LP | 6,392,628 | 60.9M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 5,782,776 | 55.1M $ | as of Mar 31, 2026 |
| Kynam Capital Management, LP | 5,680,795 | 54.1M $ | as of Mar 31, 2026 |
| BANK OF AMERICA CORP /DE/ | 5,091,765 | 48.5M $ | as of Mar 31, 2026 |
| Aberdeen Group plc | 5,040,670 | 48M $ | as of Mar 31, 2026 |
| UBS Group AG | 4,943,994 | 47.1M $ | as of Mar 31, 2026 |
| Frazier Life Sciences Management, L.P. | 4,009,240 | 38.2M $ | as of Mar 31, 2026 |
| Royalty Pharma Sub-Manager, LLC | 3,846,154 | 36.6M $ | as of Mar 31, 2026 |
| Nuveen, LLC | 3,819,263 | 36.4M $ | as of Mar 31, 2026 |
| GW&K Investment Management, LLC | 3,240,462 | 30.9K $ | as of Mar 31, 2026 |
| Eversept Partners, LP | 3,039,820 | 28.9M $ | as of Mar 31, 2026 |
| RFG Advisory, LLC | 2,870,700 | 27.3M $ | as of Mar 31, 2026 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2,815,304 | 26.8M $ | as of Mar 31, 2026 |
| Fisher Asset Management, LLC | 2,733,253 | 26M $ | as of Mar 31, 2026 |
| DIMENSIONAL FUND ADVISORS LP | 2,690,651 | 25.6M $ | as of Mar 31, 2026 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2,350,405 | 22.4M $ | as of Mar 31, 2026 |
| GOLDMAN SACHS GROUP INC | 2,347,443 | 22.3M $ | as of Mar 31, 2026 |
Declared shareholders of BioCryst Pharmaceuticals Inc
There are 2 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| Vanguard Capital Management | 5.16 % | 12,961,172 | as of Mar 31, 2026 · SCHEDULE 13G |
| STATE STREET CORPORATION | 4.90 % | 12,208,360 | as of Mar 31, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Fund shareholders of BioCryst Pharmaceuticals Inc". https://titelia.com/en/stocks/biocryst-pharmaceuticals-inc-US09058V1035